Pharma industry should go for strategic, basic science innovations-Dr. Mussadiq Malik

Print

 Global Clinical Trials and Innovations

Pharma industry should go for strategic, basic
science innovations - Dr. Mussadiq Malik

KARACHI: Special Assistant to Prime Minister Dr. Mussadiq Malik himself a Pharmacist was the chief guest at conference Dinner of 2nd Pakistan Pharma Summit held on May 3rd 2016. Speaking at the occasion he urged the pharmaceutical industry of Pakistan to explore the option of becoming a part of the global effort of running clinical trials for innovation in the field of medicines and health care research. “In order to move forward and find a Global place, Pharma industry has to go for strategic innovation, basic science innovation, go into a new industry which was growing very fast i.e. the Contract Research Organizations (CROs).Earlier clinical trials used to be conducted in North America and Europe but because of the changes that had transpired, most of the trials were now global with regional representation from all over the world.With 200 million people from South Asia having certain kind of a genetic set-up, you have to plan somewhere as there is enormous opportunity in setting up Contract Research Organizations, setting up bio-analytical organizations in Pakistan to become part of these global clinical trials,” Dr. Malik added.

Continuing Dr. Mussadiq Malik said that at present such research organizations and hospitals have been missing in Pakistan, which had the expertise of running the protocols and trials, which were practiced the world over by contract research organizations in the field of drugs’ manufacturing and innovation. He opined that Pakistani pharmaceutical industry had become stagnant because of low growth, lack of innovation in research and development (R&D) sector, doing less value creation and addition to their products.

He urged the leadership and managers of Pakistan pharmaceutical industry to create a balance in their manufacturing and products’ portfolios in order to make a differentiation in the market place. He said that at present the portfolios of pharmaceutical companies of the country had been heavily lopsided due to less emphasis on biologics and similar new and innovative trends prevailing in global Pharma sector. He was of the view that portfolios of Pakistan pharmaceutical companies could easily be balanced with minimal investment. He urged the Pakistan Pharma sector to adopt scientific, evidence, and research-based marketing strategies for their products for doing marketing on innovative lines for a long-term relationship with physicians, dispensers, retailers, and distributors related to the medicines’ market. Traditional and old marketing strategies for pharmaceutical products that tried to create leverage on basis of offering certain incentives to doctors against ethics of health care service were no more valid around the globe, he remarked. His advice to the Pakistani Pharma industry was that in addition to going after innovation of new therapeutic entities, the Pakistani drugs’ manufacturers should also do research for innovation in the field of combination therapies which does not require very heavy investment.

Pharmaceutical industry the world over, Dr. Mussdaq Malik said has been growing very fast and its volume increased from 980 billion US Dollars to 1.2 trillion US Dollars. Most of this growth in the global Pharma sector had been coming from developing economies. It is also a fact that future growth of pharmaceutical industry would be driven by developing countries including China, India, Brazil, and Pakistan, etc.,”.

Chairman of organizing committee of the Second Pakistan Pharma summit Dr. Kaiser Waheed speaking on this occasion said that around four hundred executives related to different functions of Pakistani Pharma industry attend the two-day summit. We had thirty two speakers including two guest speakers from overseas including Prof. Dr. Marcel Corstjens from France who is known as a distinguished speaker on pharmaceutical marketing.

© Professional Medical Publications. All rights reserved.